Lapaquistat Acetate

Phase 3Small molecule

Takeda

Lapaquistat Acetate is one of 54 small molecule programs targeting Hypercholesterolemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypercholesterolemiaActive, not recruiting

Homozygous Familial HypercholesterolemiaActive, not recruiting

HypercholesterolemiaPhase 3

Active, not recruiting

Homozygous Familial HypercholesterolemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

130 competitors in Hypercholesterolemia

#DrugCompanyPhaseTrials

Lescol

Novartis

Phase 3

1 2

Avapro

Sanofi

Phase 3

1 3

Micardis

Boehringer Ingelheim

Phase 3

1 4

Comparator: Statins

Merck & Co.

Phase 3

3 5

Statin

Bristol-Myers Squibb

Phase 3

2 6

Evacetrapib

Eli Lilly

Phase 3

2 7

Comparator: Pbo

Merck & Co.

Phase 3

2 8

Kynamro

KKastle Therapeutics, LLC

Phase 3

1 9

Anacetrapib

Merck & Co.

Phase 3

1 10

Bococizumab

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypercholesterolemia9 trials

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

Terminated· Takeda logo

Takeda·Phase 3·NCT00532311·411 enrolled

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

Terminated· Takeda logo

Takeda·Phase 3·NCT00249899·649 enrolled

Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia

Completed· Takeda logo

Takeda·Phase 3·NCT00286481·1,362 enrolled

Show 6 more trials

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

Completed· Takeda logo

Takeda·Phase 3·NCT00143676·448 enrolled

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

Completed· Takeda logo

Takeda·Phase 3·NCT00249912·415 enrolled

Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia

Completed· Takeda logo

Takeda·Phase 2·NCT00864643·172 enrolled

Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia

Completed· Takeda logo

Takeda·Phase 3·NCT00868127·574 enrolled

Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

Terminated· Takeda logo

Takeda·Phase 2·NCT00865228·224 enrolled

Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia

Terminated· Takeda logo

Takeda·Phase 3·NCT00532558·657 enrolled

Dyslipidemia2 trials

Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.

Completed· Takeda logo

Takeda·Phase 3·NCT00256178·411 enrolled

Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.

Completed· Takeda logo

Takeda·Phase 3·NCT00268697·1,267 enrolled

Elevated Cholesterol1 trial

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

Completed· Takeda logo

Takeda·Phase 3·NCT00143663·361 enrolled

Efficacy1 trial

Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.

Completed· Takeda logo

Takeda·Phase 3·NCT00251680·400 enrolled

Cholesterol1 trial

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

Completed· Takeda logo

Takeda·Phase 2·NCT00813527·213 enrolled

2 more indications

Homozygous Familial Hypercholesterolemia1 trial

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

Terminated· Takeda logo

Takeda·Phase 3·NCT00263081·44 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

Completed· Takeda logo

Takeda·Phase 3·NCT00487994·2,130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Lapaquistat Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lapaquistat Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lapaquistat Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Lapaquistat Acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypercholesterolemia9 trials

Dyslipidemia2 trials

Elevated Cholesterol1 trial

Efficacy1 trial

Cholesterol1 trial

Homozygous Familial Hypercholesterolemia1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News